secwatch.observer — SEC 8-K summary
======================================

Issuer:     Zomedica Corp. (ZOMDF)
CIK:        0001684144
Form:       8-K
Filed at:   2022-05-10T23:59:59+00:00
Accession:  0001654954-22-006382
Event type: earnings
Sentiment:  positive
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Zomedica Q1 revenue $3.8M, up 38% pro forma; net loss $3.9M
-----------------------------------------------------------

- Revenue $3.8M (74% gross margin) vs $14K in Q1 2021; up 38% over combined Zomedica+PulseVet $2.7M.
- PulseVet revenue $3.7M (+36% vs standalone Q1 2021); small animal unit sales 30 (+500% YoY).
- TRUFORMA product revenue $57K (+307% vs $14K); launched endogenous ACTH assay in April 2022.
- Cash $192.3M at quarter end; net loss $3.9M ($0.004/share) vs $36.0M loss in Q1 2021.
- SG&A $6.7M (+91% YoY) driven by share-based comp and sales force expansion; R&D $351K.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1684144/000165495422006382/0001654954-22-006382-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1684144/000165495422006382/zom_8k.htm
  HTML page:      https://secwatch.observer/filing/0001654954-22-006382

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer